KNSA Stock Analysis: Buy, Sell, or Hold?
KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$75.79
0.57 (0.76%)
▲
5d:
+0.95%
30d:
-5.13%
90d:
+20.74%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 27, 2026
23d
Get Alerted When KNSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KNSA trades at premium valuation expecting 12.9% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: KNSA trades at premium valuation expecting 12.9% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$78.75
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$48.90
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KNSA is currently trading at $75.79, which is considered slightly low relative to its 30-day fair value range of $75.76 to $79.19. From a valuation perspective, the stock is trading at a premium (Forward PE: 46.9) compared to its historical average (32.6). At these levels, the market is pricing in 12.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $73.14, while resistance sits at $79.54.
Market Sentiment: KNSA scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.00 (+29.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $73.14, while resistance sits at $79.54.
Market Sentiment: KNSA scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.00 (+29.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$75.76 -
$79.19
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
91.5%
Protect Your Profits
Holding KNSA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.3% below Wall St target ($98.00)
- NEUTRAL: Trading at premium valuation - market expects 12.9% growth which is achievable
- CAUTION: Bottoming setup, but lagging the sector by 20% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$75.76 -
$79.19
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$4.98
(6.6%)
Support & Resistance Levels
Support Level
$73.14
Resistance Level
$79.54
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
46.86
Wall Street Target
$98.00
(+29.3%)
Revenue Growth (YoY)
55.4%
Earnings Growth (YoY)
30.4%
Profit Margin
9.6%
Valuation Premium vs History
+12.9% premium
PE vs Historical
46.9 vs 32.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.9%
(market-implied from PE analysis)
1-Year Target
$85.57
(+13%)
2-Year Target
$96.61
(+28%)
3-Year Target
$109.07
(+44%)
3-Yr Target (if PE normalizes)
(PE: 47→33)
PE COMPRESSION
$75.88
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.9, Growth: 39.7%)
$206.81
(+173%)
Base:
(SPY PE: 20.4, Growth: 39.7%)
$90.04
(+19%)
Bear:
(PE: 17.3, Growth: 39.7%)
$76.54
(+1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (75x PE), but valuation improves significantly next year (47x PE) as earnings recover.
Trailing PE: 75.22 | Current EPS (TTM): $1.00
Bull Case
$133.84
(+77%)
Analyst growth 61.7%, PE expands to 82.7
Base Case
$121.67
(+61%)
Market implied 61.7%, PE stable at 75.2
Bear Case
$51.15
(-33%)
Severe decline -20.0%, PE contracts to 63.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 11:01 PM ET
Data refreshes hourly during market hours. Next update: 12:01 AM
Data refreshes hourly during market hours. Next update: 12:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KNSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Ross Moat
SELL
1703 shares
2026-04-09
Michael R Megna
SELL
6625 shares
2026-04-09
Barry D Quart
SELL
6901 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced KNSA Option Strategies
Professional options setups generated by AI based on today's KNSA price and gamma walls.
